Talphera (TLPH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 22, 2026, with voting on director elections, auditor ratification, executive compensation, and amendments to equity and stock purchase plans.
Stockholders can vote online, by phone, or by mail, and only those of record as of April 24, 2026, are eligible.
The Board recommends voting in favor of all proposals, including the election of three Class III directors and approval of updated incentive and stock purchase plans.
Voting matters and shareholder proposals
Proposals include electing three Class III directors, ratifying BPM LLP as auditor, advisory approval of executive compensation, and approving amended 2020 Equity Incentive and 2011 Employee Stock Purchase Plans.
The Board recommends voting FOR all proposals; most require a majority of shares present or represented by proxy.
Shareholder proposals for the 2027 meeting must be submitted by December 30, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The Board consists of eight members divided into three classes, with a majority being independent under Nasdaq rules.
Board committees include Audit, Compensation, Nominating and Corporate Governance, and Finance and Strategic Transactions, each with defined roles and independent members.
Board leadership is separated between the Chairman and CEO, and director qualifications emphasize integrity, expertise, and diversity of experience.
Latest events from Talphera
- Q2 net loss was $4.3M as nafamostat gains guideline support and CRRT market expands 21%.TLPH
Q2 2026 - All proposals, including director elections and plan amendments, were approved without shareholder questions.TLPH
AGM 2026 - NEPHRO CRRT study enrollment surpassed 50%, Q1 net loss was $2.6M, cash at $21.1M.TLPH
Q1 2026 - Annual meeting seeks approval for directors, auditor, compensation, and equity plans.TLPH
Proxy filing - Niyad targets a major gap in anticoagulation for dialysis, with pivotal study completion expected in 2026.TLPH
Corporate presentation - Resale registration for $4.1M in shares and warrants; acute care focus; no proceeds to issuer.TLPH
Registration filing - Nephro CRRT study hits 50% enrollment; $20.4M cash at year-end 2025; Niyad seen as promising.TLPH
Q4 2025 & Investor Day - Pivotal phase III trial of Niyad targets 2025 finish, with strong IP and market prospects.TLPH
Maxim Group’s 2024 Healthcare Virtual Summit - Q2 net loss narrowed to $3.8M, cash rose to $14M, and NEPHRO study enrollment accelerated.TLPH
Q2 2024